What's Happening?
Apreo Health has commenced its pivotal clinical trial, BREATHE-3, to evaluate the safety and efficacy of the BREATHE Airway Scaffold, a novel medical device designed to treat severe emphysema. The trial aims to enroll up to 250 patients across 25 sites in the U.S. and Europe, following participants for three years. The BREATHE Airway Scaffold is a bronchoscopically delivered, self-expanding implant intended to relieve lung hyperinflation in patients with emphysema who struggle with breathing despite optimal medical management. The trial builds on previous studies that demonstrated high technical success and no pneumothorax, a common complication in similar interventions.
AD
Why It's Important?
The BREATHE-3 trial represents a significant advancement in the treatment of emphysema, a severe form of chronic obstructive pulmonary disease (COPD) affecting millions in the U.S. Current treatment options are limited, with fewer than 1% of patients receiving interventional care. The success of this trial could expand access to effective treatments, improve patient outcomes, and potentially set a new standard of care for emphysema. This development is crucial as COPD remains a leading cause of death and disability, highlighting the need for innovative solutions.
What's Next?
As the trial progresses, Apreo Health will continue to monitor patient outcomes, focusing on lung function, quality of life, and exercise capacity. The results could influence future treatment protocols and healthcare policies regarding emphysema management. Stakeholders, including medical professionals and healthcare institutions, will be keenly observing the trial's outcomes to assess the potential integration of the BREATHE Airway Scaffold into standard treatment practices.
